BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37458549)

  • 21. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.
    Wang S; Medeiros LJ; Xu-Monette ZY; Zhang S; O'Malley DP; Orazi A; Zuo Z; Bueso-Ramos CE; Yin CC; Liu Z; Miranda RN; Young KH
    Ann Diagn Pathol; 2014 Aug; 18(4):203-9. PubMed ID: 24852241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metallothionein as a useful marker in Hodgkin lymphoma subclassification.
    Penkowa M; Sørensen BL; Nielsen SL; Hansen PB
    Leuk Lymphoma; 2009 Feb; 50(2):200-10. PubMed ID: 19199157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
    Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
    Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
    Xing KH; Connors JM; Lai A; Al-Mansour M; Sehn LH; Villa D; Klasa R; Shenkier T; Gascoyne RD; Skinnider B; Savage KJ
    Blood; 2014 Jun; 123(23):3567-73. PubMed ID: 24713929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
    Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
    Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nodular Lymphocyte-Predominant Hodgkin Lymphoma(NLPHL)Which Originate from the Mesentery-A Series of Two Cases].
    Zenitani S; Imasato M; Iwamoto K; Nakahara Y; Mikamori M; Naito A; Ohtsuka M; Furukawa K; Moon J; Asaoka T; Kishi K; Akamatsu H
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):1875-1877. PubMed ID: 33468858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Sakai J; Tanae K; Takahashi N; Nagata K; Yoshino T; Tamaru J; Niitsu N
    J Clin Exp Hematop; 2015; 55(1):23-8. PubMed ID: 26106003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nodular lymphocyte-predominant Hodgkin's lymphoma: Principles of diagnosis and treatment].
    Moiseeva TN; Al-Radi LS; Kovrigina AM; Goryacheva SR; Julakyan UL; Margolin OV; Skidan NI; Tseytlina MA; Kravchenko SK
    Ter Arkh; 2015; 87(11):78-83. PubMed ID: 26821421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.
    Hartmann S; Agostinelli C; Diener J; Döring C; Fanti S; Zinzani PL; Gallamini A; Bergmann L; Pileri S; Hansmann ML
    BMC Cancer; 2012 Dec; 12():586. PubMed ID: 23228169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015.
    Juntikka T; Malila N; Ylöstalo T; Merikivi M; Jyrkkiö S
    Acta Oncol; 2020 May; 59(5):574-581. PubMed ID: 31910680
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma.
    Steimle-Grauer SA; Tinguely M; Seada L; Fellbaum C; Hansmann ML
    Virchows Arch; 2003 Mar; 442(3):284-93. PubMed ID: 12647220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
    Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
    Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
    Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
    Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
    Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI; LaCasce AS
    Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.